Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Novo Nordisk Inc.
483
•Novo Nordisk Inc.•February 7, 2025

Novo Nordisk Inc. – FDA 483, Feb 7, 2025

Record Details

An FDA inspection conducted at Novo Nordisk Inc.'s corporate headquarters in Plainsboro, NJ, from January 13 to February 7, 2025, identified significant deficiencies in the company's post-marketing adverse drug experience reporting systems. The inspection revealed that the company failed to report over 300 serious and unexpected adverse drug experiences to the FDA within the required 15 calendar days, with many reports submitted substantially late, some by over a thousand days. This was partly attributed to an internal deviation identified as a "failure to transmit safety events to global safety database" and inadequacies in vendor training for adverse event surveillance, which led to an additional 700 late submissions.

Furthermore, Novo Nordisk Inc. did not promptly investigate these serious and unexpected adverse events, failing to conduct required follow-up attempts with reporters for critical cases involving outcomes like death or completed suicide related to products such as Ozempic. The company also failed to submit at least 10 required periodic Individual Case Safety Reports (ICSRs) for serious and listed events. A key contributing factor was the inadequacy of written procedures for the surveillance, receipt, and reporting of post-marketing adverse drug experiences. Specifically, the company's "Case Management Workflow" SOP was found to hinder necessary investigations and evaluations, and serious events were left uninvestigated due to issues like not obtaining reporter consent or initial rejections by case processors. The regulatory framework violated pertains to timely adverse event reporting requirements.

To address these observations, Novo Nordisk Inc. is required to implement robust corrective actions, ensuring timely and accurate submission of all adverse event reports, enhancing investigation protocols, improving vendor oversight, and revising its procedural documents to comply with regulatory requirements for drug safety reporting.

Company
Novo Nordisk Inc.
Inspection date
February 7, 2025
Product type
drugs
Office
New Jersey District Office
People
  • Tyanna N. Hadley (investigator)
  • Mayar M. Mussa
  • Ana L. Windle (Senior Vice President)
View Company Profile

ID · af90a225-6f09-44bf-9f09-4154f6541ff1

Other documents for Novo Nordisk Inc.
  • WARNING_LETTER - 2025-02-07February 7, 2025
  • WARNING_LETTER
  • CRL
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novo Nordisk Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.